Medications for Chronic Graftversushost Disease

4 results

  • imbruvica

    (Ibrutinib)
    Pharmacyclics LLC
    IMBRUVICA is indicated for treating adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), CLL/SLL with 17p deletion, Waldenström’s macroglobulinemia, and chronic graft-versus-host disease in patients aged 1 year and older after one or more prior systemic therapy failures.

  • jakafi

    (ruxolitinib)
    Incyte Corporation
    Jakafi is indicated for treating intermediate or high-risk myelofibrosis, polycythemia vera in adults intolerant to hydroxyurea, and steroid-refractory acute and chronic graft-versus-host disease in patients aged 12 and older who have not responded to prior systemic therapies.

  • niktimvo

    (axatilimab-csfr)
    Incyte Corporation
    NIKTIMVO is indicated for the treatment of chronic graft-versus-host disease (cGVHD) in adults and pediatric patients weighing at least 40 kg, following the failure of at least two prior lines of systemic therapy.

  • rezurock

    (belumosudil)
    Kadmon Pharmaceuticals, LLC
    REZUROCK is indicated for treating chronic graft-versus-host disease (GVHD) in adult and pediatric patients aged 12 and older who have not responded to at least two prior lines of systemic therapy.